Efficacy of an Infrared Visualization Technique for the Identification of the Peripheral Venous Access Site in Patients With Cystic Fibrosis Aged 12 Years and Older (MUCOVEINE)

• ClinicalTrials.gov Identifier: NCT04226118
• Recruitment Status: Completed
• First Posted: January 13, 2020
• Last Update Posted: July 7, 2022
• Sponsor: Hospices Civils de Lyon
• Information provided by (Responsible Party): Hospices Civils de Lyon

Study Description

Brief Summary:

Cystic fibrosis is a rare chronic genetic disease that mainly affects the respiratory tract and the digestive system. Their management includes multi-year intravenous antibiotic treatments and repeated venous sampling. The venous access is a source of difficulties that nurses who take care of these patients face on a daily basis. In addition, multiple attempts at punctures can induce anxiety and pain in patients. It is therefore important to limit failures.

Vein visualization technologies exist: guidance echo, portable trans lumination or infrared visualization can guide venipuncture and limit failures.

Compared with the guided echo or the portable trans lumination, the infrared visualization is easy to use and does not pose a risk for the patient. Nevertheless, studies evaluating this technique are few in chronic diseases and mainly conducted in young children.

This study aims to show that the use of a vein illumination system (VIS) should improve the peripheral venous access at the first attempt (thus limiting venous lesions) in adolescent and adult patients with cystic fibrosis, and improve comfort of the patient (pain, apprehension of the gesture).

Condition or disease	Intervention/treatment	Phase
Cystic Fibrosis	Device: Vein Illumintion System device	Not Applicable

Detailed Description:

Background :

Cystic fibrosis is a rare chronic genetic disease that mainly affects the respiratory tract and the digestive system. Their management includes multi-year intravenous antibiotic treatments and repeated venous sampling. The venous access is a source of difficulties that nurses who take care of these patients face on a daily basis. In addition, multiple attempts at punctures can induce anxiety and pain in patients. It is therefore important to limit failures.

Vein visualization technologies exist: guidance echo, portable trans lumination or infrared visualization can guide venipuncture and limit failures.

Compared with the guided echo or the portable trans lumination, the infrared visualization is easy to use and does not pose a risk for the patient. Nevertheless, studies evaluating this technique are few in chronic diseases and mainly conducted in young children.

This study aims to show that the use of a vein illumination system (VIS) should improve the peripheral venous access at the first attempt (thus limiting venous lesions) in adolescent and adult patients with cystic fibrosis, and improve comfort of the patient (pain, apprehension of the gesture).

Objectives of the study :

The main objective of the study is to demonstrate that the use of a vein illumination system (VIS) for the placement of a peripheral venous line or venous sampling on the hand, forearm or fold of the elbow improves peripheral venous access (PVA) successful on the first attempt.

The secondary objectives are :

• To study the efficacy of VIS for peripheral venous access (placement of a peripheral venous line or peripheral venous sampling in the hand, forearm or elbow) on the number of attempts.
• To study the impact of the use of SIV on the patient's pain felt during the peripheral venous access procedure.
• To study the impact of VIS on patient anxiety prior to peripheral venous access.
• To describe the nurses and nursing students satisfaction with the use of the VIS device for peripheral venous access.
• To study the determinants of the success of peripheral venous access at the first attempt among the characteristics of nurses and nursing students (age, year of obtaining their diploma, experience within the cystic fibrosis ressource and competence center).
• To describe the nurses and nursing students satisfaction with the use of A-DIVA scale.

Study design The study will last 36 months. It is an open and randomized multicenter cluster study, with sequential allocation of the device (stepped wedge allocation), comparing a group of patients benefiting from a technique of locating the puncture site by a venous illumination system for a peripheral venoux access (hand, forearm, fold of the elbow) to a group of patients whose veins are identified according to the usual modality of a peripheral venoux access. The cluster is defined by the Cystic Fibrosis Resource and Competence Center (CRCM).

Expected results

For the patients, the use of a venous illumination system device during the peripheral venous access should facilitate the success of the gesture on the first attempt, allowing to :

• Reduce their pain due to multiple attempts.
• Reduce their anxiety associated with peripheral venous access.
• Preserve their venous capital This could have an impact on their care, such as making it easier to consult for them and being less anxious about peripheral venous access.

For the nurses, using a venous illimunation system device could

• Reduce their apprehension of peripheral venous access gesture
• Save their time with fewer peripheral venous access are repeated. It is considered that this technique will be distributed to all Cytic Fibrosis Ressource and Competence Centers (CRCM) in order to improving the comfort of the chronically ill patient with repeated blood tests and intravenous treatments.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 271 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Health Services Research
• Official Title: Efficacy of an Infrared Visualization Technique for the Identification of the Peripheral Venous Access Site in Patients With Cystic Fibrosis Aged 12 Years and Older
• Actual Study Start Date: January 19, 2021
• Actual Primary Completion Date: May 12, 2022
• Actual Study Completion Date: May 12, 2022

Arms and Interventions

Arm	Intervention/treatment
No Intervention: Control Group; Patients who have a peripheral venous access by a classic procedure, without using a Vein Illumination System.
Experimental: Experimental Group; Patients who have a peripheral venous access by a procedure using a Vein Illumination System.	Device: Vein Illumintion System device; Spotting veins of a patient by use of a Vein Illumintion System device

Outcome Measures

Primary Outcome Measures :

1. Proportion of patients for whom peripheral venous access was performed from the first attempt. [ Time Frame: at time of peripheral venous access ]

Secondary Outcome Measures :

1. Number of attempts to place a peripheral venous line or perform peripheral venous [ Time Frame: at time of peripheral venous access ]
2. Average pain score on Visual Analogue Scale (VAS) after successful peripheral venous access act. [ Time Frame: at most 10 min after the venous act ]
3. Average anxiety score on State-Trait Anxiety Inventory (STAI-Y) [ Time Frame: at most 10 min before the venous act ]
4. Proportion of nurses and nursing student satisfied by the use of a vein illumination system [ Time Frame: at the end of the study ( at 14 months) ]

Eligibility Criteria

• Ages Eligible for Study: 12 Years and older (Child, Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Patients with cystic fibrosis aged 12 years and over
• Cystic Fibrosis diagnosis has been confirmed by a positive sweat test and/or 1 to 2 genetic mutations
• Patients requiring peripheral venous access (hand, forearm, or more of the elbow) for intravenous infusion with epicranial or short catheter, or for a blood sample
• Patients who have a score of 4 or higher on the A-DIVA scale (self-administered questionnaire completed by the IDE assessing the difficulty of peripheral venous access on a Likert scale from 0 to 8)
• Patients informed in writing of the terms of the study and provided written informed consent to participate (consent of the person in charge of parental authority if the patient is a minor).
• Patients affiliated to a social security system

Exclusion Criteria:

• Patient who has already participated in the study
• Patients who have a central venous approach
• Patients who have a venous approach of the midline type
• Patients taken care of for vital emergency
• Patient deprived of liberty or placed under tutorship or curatorship

Contacts and Locations

Locations

France

CRCM mixte de Giens

Giens, France, 83406

Hôpital Nord - CRCM adulte Marseille

Marseille, France, 13015

Hôpital enfant la Timone - CRCM pédiatrique Marseille

Marseille, France, 13385

Hôpital Arnaud de Villeneuve

Montpellier, France, 34090

Hôpital Pasteur - CRCM adulte Nice

Nice, France, 06001

Hôpital Lenval - CRCM pédiatrique Nice

Nice, France, 06202

Sponsors and Collaborators

Hospices Civils de Lyon

More Information

• Responsible Party: Hospices Civils de Lyon
• ClinicalTrials.gov Identifier: NCT04226118
• Other Study ID Numbers: 69HCL19_0036
• First Posted: January 13, 2020
• Last Update Posted: July 7, 2022
• Last Verified: July 2022

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Cystic Fibrosis; Fibrosis; Pathologic Processes; Pancreatic Diseases; Digestive System Diseases; Lung Diseases; Respiratory Tract Diseases; Genetic Diseases, Inborn; Infant, Newborn, Diseases